Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Markers in the Early Diagnosis and Prognostic Evaluation of...
share announcement

New Markers in the Early Diagnosis and Prognostic Evaluation of Ovarian Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 4763

Special Issue Editor

Dr. Francesco Raspagliesi

E-Mail Website
Guest Editor
IRCCS Ist Nazl Tumori Milano, Gynecol Oncol Unit, I-20133 Milan, Italy
Interests: ovarian neoplasms; uterine cervical neoplasms; gynecological cancer

Special Issue Information

Dear Colleagues,

Gynecological cancers represent one of the leading causes of cancer-related deaths in women. Compared to other types of cancer, gynecological cancers are uncommon, but their incidence is increasing, likely attributable to the aging of populations and increased prevalence of obesity in the developed world. The main types of gynecological cancer that affect a woman's reproductive organs are cervical, ovarian, uterine, vaginal, and vulvar tumors. The mainstay of treatment for gynecological cancer includes multimodal therapy with optimal surgery, chemotherapy, and radiotherapy. The introduction of effective screening methods and efforts to achieve early diagnoses will allow improving the outcomes of these patients. In recent years, the introduction of innovative diagnostic methods and innovative surgical, as well as medical, treatments have improved early detection and the outcomes for gynecological cancer patients. The objective of the current Special Issue in Cancers is to publish original research papers and reviews from authors who are interested in addressing these challenges and provide new insights and novel treatment strategies for patients with gynecological cancer.

Dr. Francesco Raspagliesi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological cancers
  • early detection
  • novel treatment strategies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1782 KiB  
Article
Shallow Whole-Genome Sequencing of Cell-Free DNA (cfDNA) Detects Epithelial Ovarian Cancer and Predicts Patient Prognosis
by Seong Eun Bak, Hanwool Kim, Jung Yoon Ho, Eun-Hae Cho, Junnam Lee, Sung Min Youn, Seong-Woo Park, Mi-Ryung Han, Soo Young Hur, Sung Jong Lee and Youn Jin Choi
Cancers 2023, 15(2), 530; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15020530 - 15 Jan 2023
Cited by 1 | Viewed by 2940
Abstract
Despite the progress in diagnostics and therapeutics, epithelial ovarian cancer (EOC) remains a fatal disease. Using shallow whole-genome sequencing of plasma cell-free DNA (cfDNA), we investigated biomarkers that could detect EOC and predict survival. Plasma cfDNA from 40 EOC patients and 20 healthy [...] Read more.
Despite the progress in diagnostics and therapeutics, epithelial ovarian cancer (EOC) remains a fatal disease. Using shallow whole-genome sequencing of plasma cell-free DNA (cfDNA), we investigated biomarkers that could detect EOC and predict survival. Plasma cfDNA from 40 EOC patients and 20 healthy subjects were analyzed by shallow whole-genome sequencing (WGS) to identify copy number variations (CNVs) and determine the Z-scores of genes. In addition, we also calculated the genome-wide scores (Gi scores) to quantify chromosomal instability. We found that the Gi scores could distinguish EOC patients from healthy subjects and identify various EOC histological subtypes (e.g., high-grade serous carcinoma). In addition, we characterized EOC CNVs and demonstrated a relationship between RAB25 amplification (alone or with CA125), and disease-free survival and overall survival. This study identified RAB25 amplification as a predictor of EOC patient survival. Moreover, we showed that Gi scores could detect EOC. These data demonstrated that cfDNA, detected by shallow WGS, represented a potential tool for diagnosing EOC and predicting its prognosis. Full article
(This article belongs to the Special Issue New Markers in the Early Diagnosis and Prognostic Evaluation of Ovarian Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 2180 KiB  
Review
Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
by Yohann Dabi, Amélia Favier, Léo Razakamanantsoa, Léa Delbos, Mathieu Poilblanc, Philippe Descamps, Francois Golfier, Cyril Touboul, Sofiane Bendifallah and Emile Daraï
Cancers 2023, 15(5), 1539; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15051539 - 28 Feb 2023
Viewed by 1256
Abstract
Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no [...] Read more.
Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no consensus exists on the best strategy between “single test”, “dual testing”, “sequential testing”, “multiple testing options” and “no testing”. In addition, there is a need for prognostic tools such as biological markers of recurrence and theragnostic tools to detect women not responding to chemotherapy in order to adapt therapies. Non-coding RNAs are classified as small or long based on their nucleotide count. Non-coding RNAs have multiple biological functions such as a role in tumorigenesis, gene regulation and genome protection. These ncRNAs emerge as new potential tools to differentiate benign from malignant tumors and to evaluate prognostic and theragnostic factors. In the specific setting of ovarian tumors, the goal of the present work is to offer an insight into the contribution of biofluid non-coding RNAs (ncRNA) expression. Full article
(This article belongs to the Special Issue New Markers in the Early Diagnosis and Prognostic Evaluation of Ovarian Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop